QPPV.COM

What Is a Concerned Member State (CMS) in EU Regulatory Affairs?

A detailed guide to the Concerned Member State (CMS), explaining its legal and scientific role in MRP and DCP, relationship with the RMS, participation in regulatory decisions, and significance for pharmacovigilance and regulatory affairs.

Audio Lesson 10 min
Knowledge Assessment Test your understanding of this article. Take the assessment →

What Is a Concerned Member State (CMS) in EU Regulatory Affairs?

Introduction

The Concerned Member State (CMS) is a Member State in which an application for a medicinal product has been submitted under the mutual-recognition procedure (MRP) or decentralised procedure (DCP), while another Member State acts as the Reference Member State (RMS) and leads the assessment.

That definition is straightforward.

The regulatory role is more important than the terminology suggests.

A CMS is not merely a country in which a company wants to sell a medicine.

It is a national competent authority participating in a coordinated European regulatory procedure.

The CMS reviews the assessment prepared by the RMS, participates in scientific and regulatory discussion, considers the proposed product information and, once agreement is reached, adopts the applicable national marketing-authorisation decision.

EMA defines a CMS as an EEA country in which an application has been submitted for authorisation through the mutual-recognition or decentralised procedure, with the assessment performed by another country acting as RMS. 1

The legal framework is principally found in Chapter 4 of Directive 2001/83/EC.

Article 28 provides for an application in more than one Member State, designation of an RMS and participation of the Member States concerned. Article 28(5) provides that each participating Member State adopts a decision in conformity with the approved assessment report, SmPC, labelling and package leaflet after agreement has been reached. 2

The central concept is therefore:

The RMS leads the assessment; the CMS participates in that assessment and retains its national regulatory responsibility within the coordinated procedure.

1. What Does CMS Mean?

CMS means:

Concerned Member State.

In the context of human medicinal products, it refers to a Member State participating in an MRP or DCP other than the RMS.

A simple representation is:

Applicant
    |
    v
   RMS
    |
    +----------------+
    |                |
    v                v
  CMS 1            CMS 2
    |                |
    +--------+-------+
             |
             v
   Coordinated procedure
             |
             v
    National decisions

The RMS leads the assessment.

The CMSs participate in the procedure.

The final regulatory outcome is implemented through the competent authorities of the participating Member States.

2. Where Does the CMS Fit in the EU Regulatory System?

The CMS concept belongs principally to the MRP/DCP framework.

It should therefore be distinguished from the centralised procedure.

For a centralised procedure:

Applicant
   |
   v
  EMA
   |
   v
 CHMP
   |
   v
European Commission
   |
   v
Union authorisation

For an MRP/DCP:

Applicant
   |
   v
   RMS
   |
   +----------------+
   |                |
   v                v
  CMS              CMS
   |                |
   +--------+-------+
            |
            v
  National authorisations

The CMS is therefore part of the national-authority network operating through a coordinated EU procedure.

3. The Legal Foundation

Article 28 of Directive 2001/83/EC establishes the framework for applications seeking marketing authorisation in more than one Member State.

The applicant submits an application based on an identical dossier in the relevant Member States and identifies the Member States concerned by the application.

The applicant requests one Member State to act as RMS and prepare an assessment report.

The other participating Member States are the CMSs. 3

The legislation therefore establishes the basic architecture:

One RMS + one or more CMSs.

This is the structural foundation of MRP and DCP.

4. The CMS Is a Regulatory Authority, Not a Geographic Label

The term "Member State" can make the CMS appear geographic.

But regulatory responsibility is the more important concept.

The CMS represents the competent regulatory authority of the participating Member State within the procedure.

Its role includes scientific and regulatory review.

Therefore, it is better to think of:

CMS = participating national regulatory authority

rather than:

CMS = country where the product will be marketed.

The latter is incomplete.

5. CMS in the Decentralised Procedure

The DCP is used when a medicinal product has not yet received a marketing authorisation in the EU and the applicant seeks authorisation in several Member States.

The structure is:

No existing EU national MA
          |
          v
         DCP
          |
          v
        RMS
          |
   +------+------+
   |             |
   v             v
 CMS 1         CMS 2
   |             |
   +------+------+
          |
          v
    Agreement
          |
          v
  National MAs

The RMS performs the principal assessment.

The CMSs review and participate in that assessment.

6. CMS in the Mutual-Recognition Procedure

MRP starts from a different regulatory position.

A medicinal product already has a marketing authorisation in one Member State.

That Member State acts as RMS.

The applicant seeks recognition in additional Member States.

Those additional Member States are CMSs.

The structure is:

Existing national MA
        |
        v
       RMS
        |
        v
 Assessment report
        |
        v
   MRP request
        |
   +----+----+
   |         |
   v         v
 CMS 1     CMS 2
   |         |
   +----+----+
        |
        v
   Recognition
        |
        v
National MAs maintained
or granted in CMSs

Article 28 specifically provides that, where the medicinal product has already received a marketing authorisation, the CMSs recognise the marketing authorisation granted by the RMS, subject to the applicable procedure. 4

7. RMS Versus CMS

The relationship can be summarised as follows:

Feature RMS CMS
Meaning Reference Member State Concerned Member State
Principal role Leads assessment Participates in assessment
Assessment report Prepares/maintains Reviews
Scientific comments Coordinates and responds Provides comments and questions
National authority Yes Yes
Product-specific role Lead authority Participating authority
MRP Existing authorisation provides basis Recognises according to procedure
DCP Leads assessment Reviews assessment
Disagreement Coordinates procedure Can raise qualifying concerns
Final national MA RMS Member State issues/maintains its national MA CMS issues/maintains its national MA

The CMS is therefore not subordinate to the RMS in the sense of losing its national regulatory authority.

The two authorities have different roles within the same procedure.

8. Is the CMS Allowed to Question the RMS?

Yes.

This is one of the most important concepts in understanding the system.

The CMS reviews the scientific assessment and can raise questions or identify concerns.

The purpose of the MRP/DCP framework is not to eliminate independent national scientific review.

It is to create a coordinated system in which that review occurs within a common procedure.

The CMS therefore has a meaningful role in scientific scrutiny.

9. Why Is CMS Review Necessary?

The EU system combines two principles:

  1. scientific and regulatory harmonisation;
  2. national competent-authority responsibility.

The CMS mechanism helps reconcile these principles.

Without CMS participation, the procedure would effectively become a centralised assessment conducted by one Member State.

That is not what MRP/DCP is.

Instead:

One authority leads; multiple authorities participate.

This distinction is fundamental.

10. What Does a CMS Review?

The CMS can review the scientific and regulatory material supporting the proposed authorisation.

Depending on the procedure and application, this may include:

The precise depth and allocation of work depends on the procedure.

The CMS does not simply review whether the RMS has completed its paperwork.

It participates in the regulatory assessment.

11. CMS Review of the Assessment Report

The RMS prepares the assessment report.

The CMS reviews it.

The CMS may ask:

The assessment therefore involves scientific dialogue.

A simplified model is:

RMS assessment
      |
      v
Assessment report
      |
      v
   CMS review
      |
 +----+----+
 |         |
 v         v

Agree Questions | | | v | RMS/applicant | response | | +----<----+ | v Agreement

This is a teaching model rather than a legal workflow.

12. The CMS and Scientific Questions

A CMS may identify an issue requiring clarification.

Examples might include:

The CMS communicates its concerns through the applicable procedure.

The RMS then coordinates the response.

13. CMS and Pharmacological Plausibility

Pharmacological plausibility can be relevant when a CMS evaluates a safety concern.

Suppose an adverse event is reported with a medicine affecting a physiological pathway.

A biologically plausible mechanism may support the hypothesis that the medicine could contribute to the event.

But the CMS should distinguish:

known pharmacology

from:

mechanistic inference

and from:

established causality.

A plausible mechanism is evidence.

It is not automatically proof.

A rigorous assessment integrates mechanism with other evidence such as:

This distinction is essential in regulatory scientific writing.

14. CMS and the Benefit-Risk Balance

The CMS participates in evaluating whether the overall benefit-risk balance supports authorisation.

This is not equivalent to asking whether the product has no risks.

Medicinal products inevitably have risks.

The regulatory question is whether:

the benefits of the medicine outweigh its risks under the proposed conditions of use.

The CMS may therefore consider:

The scientific reasoning should remain explicit.

15. CMS and Product Information

The CMS participates in review of the:

Article 28 specifically links the final national decisions to the approved assessment report, SmPC, labelling and package leaflet. 5

Product information is therefore not a secondary administrative document.

It is part of the regulatory outcome.

16. Why Product Information Matters to Pharmacovigilance

For pharmacovigilance, product information defines important regulatory context.

For example, an adverse event can be:

The current approved product information therefore matters when interpreting safety information.

A CMS participating in regulatory review can contribute to how safety information is reflected in the authorised product information.

17. CMS and Risk Management

The CMS may also review risk-management information within the applicable regulatory framework.

This can involve:

The CMS does not independently create a separate risk-management system for the product.

Rather, it participates in the coordinated regulatory assessment.

18. CMS and the Final National Decision

A crucial distinction is that agreement at the European procedural level does not mean that one single national authority grants every national authorisation.

Article 28(5) provides that each Member State in which the application has been submitted adopts a decision in conformity with the agreed assessment report, SmPC, labelling and package leaflet. 6

Thus:

Coordinated agreement
        |
        v
 +------+------+------+
 |      |      |      |
 v      v      v      v
MS1    MS2    MS3    MS4
 |      |      |      |
 v      v      v      v

National National National National MA MA MA MA

The CMS remains relevant because the final authorisation is implemented through its national competent authority.

19. The CMS Does Not Issue a Union Marketing Authorisation

This is an important distinction.

A CMS does not issue a central EU marketing authorisation.

Instead, in the MRP/DCP framework, the participating Member States issue or maintain national marketing authorisations in accordance with the agreed regulatory outcome.

This is one of the fundamental differences between:

MRP/DCP

and:

centralised procedure.

20. CMS and CMDh

The CMS operates within the broader coordination framework provided by CMDh.

EMA describes CMDh as the group responsible for examining and coordinating questions concerning marketing authorisations of human medicines in two or more Member States under MRP/DCP. 7

The distinction is:

CMS

A national competent authority participating in a specific product procedure.

CMDh

A European coordination group dealing with questions across the MRP/DCP system.

Therefore:

CMS is a role in a product procedure; CMDh is a European coordination mechanism.

21. CMS Representation in CMDh

CMDh is composed of representatives from the Member States.

The practical significance is that national regulatory authorities participate in European coordination through the group.

This provides a mechanism for dealing with issues that cannot simply be resolved through bilateral RMS-CMS communication.

The CMS therefore has a connection to the European coordination structure without becoming identical to CMDh.

22. What Happens If a CMS Disagrees?

This is where the CMS role becomes particularly important.

Article 29 of Directive 2001/83/EC addresses disagreement during MRP/DCP.

If, within the relevant period, a Member State cannot approve the assessment report, SmPC, labelling or package leaflet on the grounds of a potential serious risk to public health, it must provide a detailed explanation of its position.

The points of disagreement are then referred to the coordination group. 8

The CMS therefore has a formal mechanism for raising a qualifying objection.

23. "Potential Serious Risk to Public Health" Is a Specific Threshold

This phrase should not be used as a synonym for:

Article 29 specifically links the disagreement mechanism to a potential serious risk to public health. 9

The European Commission has also issued a guideline defining the concept for the purposes of Article 29. 10

Therefore, an organisation should not label every CMS question as an Article 29 objection.

The procedural threshold matters.

24. CMS Disagreement: The First Step

If the CMS has a qualifying concern, it provides a detailed explanation.

The concern should be scientifically and regulatorily reasoned.

It should identify:

The CMS should not simply state:

"We disagree."

A regulatory objection requires reasoning.

25. CMS Disagreement and CMDh

Once the qualifying points of disagreement are referred to CMDh, the Member States seek agreement.

Article 29 provides a 60-day period for the Member States to use their best endeavours to reach agreement. The applicant is also given an opportunity to make its views known orally or in writing. 11

The simplified structure is:

CMS objection
      |
      v
Detailed reasons
      |
      v
    CMDh
      |
      v
Scientific discussion
      |
      v
   Agreement?
    /     \
  Yes      No
   |        |
   v        v

Procedure Union-level continues escalation | v EMA/ CHMP pathway

The exact legal steps depend on the procedure.

26. CMS Is Not "Overruled" Simply Because It Is a CMS

It is incorrect to think:

RMS = decision-maker

CMS = subordinate reviewer.

The system does not work that way.

The CMS has a defined regulatory role.

Where a CMS raises a qualifying public-health objection, the EU framework provides a formal route for resolving the disagreement.

This is a coordinated regulatory system, not a hierarchy in which the RMS simply overrules the CMS.

27. What Happens If CMDh Reaches Agreement?

If the Member States reach agreement within the applicable process, the RMS records the agreement and closes the procedure according to Article 29.

The participating Member States then adopt their national decisions in accordance with the agreed outcome. 12

The CMS therefore remains responsible for implementation within its national regulatory framework.

28. What Happens If CMDh Cannot Reach Agreement?

If agreement cannot be reached within the applicable 60-day period, Article 29 provides for the Agency to be informed so that the relevant Union procedure can be applied. 13

EMA describes this as the escalation of the disagreement toward the CHMP procedure in the applicable circumstances. 14

The important teaching point is:

A CMS objection can become the starting point of a Union-level regulatory process.

This is one reason the CMS role is more significant than a simple administrative designation.

29. CMS and the Applicant

The CMS does not normally become the applicant's informal scientific adviser.

The applicant remains responsible for its submission and responses.

The regulatory communication follows the applicable procedural framework.

The RMS often coordinates communication during the procedure.

This creates a useful distinction:

Applicant

→ provides evidence and responses.

RMS

→ leads and coordinates assessment.

CMS

→ independently participates in review.

CMDh

→ provides European coordination where applicable.

30. CMS and Regulatory Questions

A CMS may identify questions concerning:

The applicant should therefore treat CMS questions as substantive regulatory questions.

A weak response may create further questions.

A strong response should:

  1. identify the exact issue;
  2. state the evidence;
  3. distinguish fact from inference;
  4. explain the scientific reasoning;
  5. address uncertainty;
  6. explain the regulatory consequence.

This is particularly important for safety-related questions.

31. CMS and Safety Signals

Suppose a CMS identifies a potential safety signal during an MRP or DCP.

The scientific assessment may include:

The CMS may question whether the proposed regulatory position adequately reflects the evidence.

The RMS then coordinates the assessment and response.

The scientific issue should remain separate from the procedural label.

A signal is not automatically an Article 29 issue.

32. Signal Detection Does Not Equal Article 29

This distinction is particularly important for pharmacovigilance professionals.

Consider:

A CMS identifies three serious cases.

That is a safety signal.

It does not automatically mean:

Article 29 disagreement.

To reach the Article 29 pathway, the relevant legal conditions must be met, including the potential serious risk to public health threshold.

Therefore:

Safety signal
     |
     v
Scientific assessment
     |
     v
Regulatory significance
     |
     v
Does the legal Article 29
threshold apply?
     |
  +--+--+
  |     |
 No    Yes
  |     |
  v     v

Routine Formal pathway disagreement pathway

This distinction prevents unnecessary escalation.

33. CMS and Emerging Safety Issues

An emerging safety issue may require rapid attention.

But the appropriate regulatory pathway must still be determined from:

A CMS may become central to the discussion if the issue affects an MRP/DCP procedure.

However, the CMS designation itself does not determine whether the issue is an emerging safety issue.

The scientific and regulatory facts do.

34. CMS and Pharmacovigilance

For pharmacovigilance teams, CMS information matters because nationally authorised medicines may have multiple participating Member States.

A safety issue may therefore need to be considered across:

The regulatory architecture should be understood before deciding how the safety issue should be escalated.

35. CMS and the QPPV

The QPPV does not replace the CMS.

Nor does the QPPV normally communicate with every CMS personally about every safety issue.

The QPPV's role is oversight.

For an MRP/DCP product, the QPPV should nevertheless be able to answer:

This is regulatory literacy, not delegation of regulatory responsibility to the QPPV.

36. CMS and the Current Product Information

A safety assessment should always use the current authorised product information.

For a nationally authorised medicine, the organisation should be able to establish the relevant national status.

Where the product is authorised through MRP/DCP, the organisation should understand:

The CMS operates within this regulatory environment.

37. CMS and National Implementation

Once agreement has been reached through the MRP/DCP process, the participating Member States adopt national decisions.

This is important because:

European procedural agreement does not mean that national regulatory administration disappears.

The CMS authority remains responsible for the national decision.

Article 28(5) expressly provides for each Member State to adopt a decision consistent with the agreed assessment and product information. 15

38. CMS and Post-Authorisation Changes

The CMS role can continue after initial authorisation.

Depending on the procedure, CMSs may participate in:

The exact mechanism depends on the legal procedure.

The important point is that:

CMS is not necessarily a one-time role associated only with the initial application.

39. CMS and Variations

A variation can affect:

For MRP/DCP products, the variation framework provides coordinated procedures involving the relevant authorities.

The CMS may therefore review the scientific basis for a proposed change.

For a safety-related variation, the CMS may assess whether the new information supports changes to:

40. CMS and Safety-Related Regulatory Procedures

The CMS also participates in the wider EU system for safety of nationally authorised medicines.

EMA explains that CMDh examines safety questions concerning non-centrally authorised medicines and can adopt positions on EU referral procedures following PRAC recommendations where applicable. 16

This is important because a CMS is part of a wider regulatory network.

A safety issue can therefore move through several levels:

Product safety issue
      |
      v
National authority
      |
      v
RMS/CMS coordination
      |
      v
    CMDh
      |
      v
     PRAC
      |
      v
CMDh / CHMP
as applicable

The exact route depends on the legal basis.

41. CMS Versus PRAC

These roles should never be conflated.

CMS

A national competent authority participating in an MRP/DCP.

PRAC

The EU committee responsible for pharmacovigilance risk assessment within its legal remit.

A CMS may participate in the European system through its Member State representation.

But CMS and PRAC describe different regulatory concepts.

42. CMS Versus CMDh

Likewise:

CMS

A participating Member State for a specific MRP/DCP procedure.

CMDh

A European coordination group for questions concerning human medicines authorised in two or more Member States through MRP/DCP. 17

The difference is:

CMS is a participant; CMDh is a coordination body.

43. CMS Versus RMS

The easiest way to remember the difference is:

RMS leads.

CMS participates.

But "participates" should not be interpreted as "rubber-stamps."

The CMS:

44. CMS Versus a National Procedure

A national procedure involves one Member State acting independently within the national authorisation framework.

A CMS participates in a European MRP/DCP procedure involving several Member States.

Therefore:

National procedure CMS role in MRP/DCP
One national procedure Part of coordinated European procedure
No RMS/CMS structure RMS + CMS structure
National assessment Coordinated assessment
National decision National decision following coordinated procedure

This distinction is important when reviewing regulatory histories.

45. A Worked DCP Example

Consider a medicine that has not yet been authorised in the EU.

The applicant seeks authorisation in:

Germany is selected as RMS.

France, Spain and Italy are CMSs.

The RMS prepares the assessment.

The CMSs review it.

Suppose France raises a significant question about the safety database.

France does not become the RMS.

Germany does not simply ignore the question.

The issue is addressed within the DCP.

If the concern is resolved, the procedure proceeds.

If a qualifying potential serious risk to public health remains and agreement cannot be reached, the Article 29 mechanism can become relevant.

46. A Worked MRP Example

Now consider a product already authorised in Germany.

The company seeks recognition in:

Germany is RMS.

France, Spain and Italy are CMSs.

The CMSs review the existing assessment and product information within the MRP.

If agreement is reached, the CMSs recognise the outcome and issue the applicable national decisions.

The important difference from DCP is the starting point:

An existing national authorisation already exists.

47. A Worked Safety Example

Suppose an MRP product has a new cluster of serious hepatic events.

The pharmacovigilance team performs a signal assessment.

Evidence includes:

The company concludes that further regulatory assessment is necessary.

The regulatory team maps:

The CMSs therefore become part of the regulatory landscape even though the original safety signal was detected by the MAH.

48. A Worked Mechanistic Example

Suppose a drug inhibits an enzyme involved in hepatic metabolism.

A new adverse-event pattern suggests liver injury.

The mechanism provides biological plausibility.

But the assessment should distinguish:

Known

The drug inhibits the enzyme.

Observed

Patients have developed a particular clinical pattern.

Plausible

The pharmacology could contribute to the observed injury.

Not yet established

The mechanism is the cause of the clinical events.

This distinction should appear explicitly in high-quality regulatory writing.

A CMS should not be presented as concluding causality solely from pharmacological plausibility.

49. What a Strong CMS Response Looks Like

Suppose the CMS asks:

"Please justify why the proposed warning is sufficient."

A strong regulatory response would address:

  1. the safety evidence;
  2. the severity and frequency;
  3. the exposed population;
  4. relevant literature;
  5. mechanistic evidence;
  6. alternative explanations;
  7. clinical management;
  8. proposed wording;
  9. residual uncertainty;
  10. why the proposed measure is proportionate.

The response should not simply state:

"The risk is considered manageable."

It should explain why.

50. CMS and Regulatory Scientific Writing

Good regulatory writing should make three things visible:

Evidence

What is actually known?

Interpretation

What does the evidence reasonably suggest?

Uncertainty

What remains unresolved?

For example:

"The observed cases are compatible with a causal association."

is different from:

"The product causes the adverse reaction."

The first expresses an evidence-based interpretation.

The second asserts causality.

The distinction is essential.

51. CMS and the Principle of Proportionality

Regulatory action should be proportionate to the evidence and risk.

A CMS may consider whether:

The objective is not to eliminate every uncertainty.

It is to ensure that the remaining uncertainty is acceptable in the context of the benefit-risk balance and proposed conditions of use.

52. CMS and Inspection Readiness

For an MAH, inspection readiness should include the ability to reconstruct the relationship with RMS and CMSs.

Relevant records can include:

The exact records depend on the procedure.

The principle is:

The regulatory decision should be reconstructable from contemporaneous records.

53. What an Inspector May Ask

An inspector could reasonably ask:

The organisation should be able to answer these questions without reconstructing the regulatory history from scattered emails.

54. CMS and Regulatory Governance

A mature regulatory governance system should have clear ownership of:

This prevents a common organisational failure:

Regulatory Affairs knows the RMS, but Pharmacovigilance does not.

Or:

Pharmacovigilance knows about the safety issue, but the regulatory database does not identify the participating Member States.

The systems need to connect.

55. CMS and Pharmacovigilance Signal Management

When a signal is identified, the organisation should not immediately ask:

"Which authority do we notify?"

A better sequence is:

Signal detected
      |
      v
Scientific assessment
      |
      v
Regulatory significance
      |
      v
Product mapping
      |
      v
Authorisation route
      |
      v
RMS / CMS mapping
      |
      v
Applicable regulatory procedure
      |
      v
Regulatory action

This avoids confusing scientific signal management with regulatory procedure selection.

56. CMS and Emerging Safety Issues

An urgent safety concern may require rapid coordination.

The CMS structure can become important because a product may be authorised in several Member States.

But urgency does not change the fundamental principle:

The applicable legal procedure must be identified from the facts.

A company should not assume that every urgent safety issue requires an Article 29 procedure.

Nor should it assume that every CMS concern represents an emerging safety issue.

Scientific classification and regulatory classification are related but distinct.

57. The CMS and the MAH

The MAH remains responsible for maintaining the medicinal product's regulatory and pharmacovigilance obligations.

The CMS is a regulator.

The relationship should therefore be understood as:

MAH
 |
 | regulatory submission/
 | scientific response
 v
RMS
 |
 | coordinated assessment
 v
CMSs

The MAH does not control the CMS.

The CMS does not manage the MAH's pharmacovigilance system.

Each party has a defined role.

58. The CMS and National Authority Independence

The CMS retains its national regulatory responsibilities.

This is important because an MRP/DCP is a mechanism for coordination and mutual reliance, not a transfer of all national authority to the RMS.

Once the procedure is concluded, each Member State adopts the applicable national decision in accordance with the agreed outcome. 18

The national authority therefore remains part of the regulatory lifecycle.

59. Why CMS Matters to the Regulatory History

A regulatory history that records only:

"DCP completed."

is incomplete.

A useful regulatory history should identify:

This makes the regulatory history intelligible to someone who was not involved in the original procedure.

60. CMS in Regulatory Master Data

For a robust regulatory database, the following fields can be useful:

Field Purpose
Product Identifies the medicinal product
Procedure type MRP or DCP
Procedure number Identifies the procedure
RMS Identifies lead authority
CMS list Identifies participating Member States
National MA number Links national authorisations
Current status Shows regulatory status
Product-information version Identifies current authorised text
Variation history Shows subsequent changes
Safety procedures Links pharmacovigilance-related action
Referral history Links EU-level procedures

The exact data model should reflect the organisation's regulatory system.

61. Why CMS Data Should Be Controlled

CMS information can change over the product lifecycle.

For example:

Therefore, CMS information should be version-controlled where appropriate.

The organisation should be able to establish:

Which Member States were concerned at a particular regulatory point in time?

This is particularly valuable during inspection or historical safety review.

62. CMS and Regulatory Intelligence

Regulatory intelligence teams may need to track:

Knowing the CMS structure helps identify which authorities may be relevant to a regulatory development.

However, a CMS designation should not be treated as proof that a particular authority has taken a specific regulatory position.

The underlying document should always be reviewed.

63. CMS and Evidence-Based Decision Making

A high-quality CMS assessment should distinguish:

Data

from:

interpretation

from:

regulatory conclusion.

For example:

Data
  |
  v
14 serious cases
  |
  v
Clinical assessment
  |
  v
Possible causal association
  |
  v
Benefit-risk analysis
  |
  v
Regulatory conclusion

This structure prevents conclusions from appearing stronger than the underlying evidence.

64. What the CMS Does Not Do

The CMS does not:

Its role is defined by the applicable regulatory procedure.

65. The Most Important Distinction: Participation Versus Independence

The CMS participates in a coordinated procedure.

But participation does not mean absence of regulatory judgement.

The CMS has its own competent authority.

It can review the evidence.

It can raise questions.

It can identify concerns.

It can participate in agreement.

Where the legal threshold is met, it can invoke the formal disagreement mechanism.

This combination of coordination and national regulatory responsibility is central to the EU system.

66. CMS and Article 29: A Practical Mental Model

Remember the sequence:

MRP / DCP
    |
    v
RMS assessment
    |
    v
CMS review
    |
    v
Agreement?
  /     \
Yes      No
 |        |
 v        v

Procedure Is there a continues potential serious risk to public health? | +---+---+ | | No Yes | | v v Resolve within Article 29 applicable route mechanism | v CMDh | v If unresolved: Union procedure

This is a conceptual teaching diagram.

The exact procedural requirements must be read from the applicable legislation and current guidance.

67. A CMS Question Is Not Necessarily a Disagreement

This is another important distinction.

A CMS may ask:

"Please provide additional justification."

That is not necessarily a formal disagreement.

A CMS may ask:

"Please clarify the denominator used in the analysis."

Again, not necessarily a formal disagreement.

A formal Article 29 situation requires the specific legal circumstances and threshold to be met.

Therefore, organisations should distinguish:

This improves regulatory tracking.

68. CMS and the Scientific Review Cycle

The CMS role can be understood as a cycle:

Review
  |
  v
Question
  |
  v
Evidence
  |
  v
Discussion
  |
  v
Revised assessment
  |
  v
Agreement

This cycle is normal.

A question from a CMS is not evidence that the application is failing.

It is part of regulatory scientific review.

69. CMS and Regulatory Quality

A well-functioning CMS process should improve:

The objective is not merely procedural agreement.

The objective is a scientifically justified regulatory outcome.

70. A Practical Checklist for Regulatory Affairs

For each MRP/DCP product, confirm:

This is a practical control rather than a legal checklist.

71. A Practical Checklist for Pharmacovigilance

For Pharmacovigilance, ask:

Again, this is an operational framework rather than a statutory checklist.

72. A Practical Checklist for the QPPV

The QPPV does not need to memorise every procedural detail.

But for a significant safety issue, the QPPV should be able to establish:

  1. Which products are affected?
  2. Which Member States are affected?
  3. What is the authorisation route?
  4. Who is the RMS?
  5. Who are the CMSs?
  6. What is the current regulatory position?
  7. What evidence supports the safety concern?
  8. What is known versus uncertain?
  9. What regulatory action is being considered?
  10. What is the documented decision and rationale?

This is the level of regulatory literacy that supports effective pharmacovigilance oversight.

73. Common Misconception: CMS Means "Secondary Country"

This terminology is misleading.

The CMS is not simply a secondary commercial market.

It is a participating Member State regulatory authority.

The CMS has a defined role in reviewing the assessment and implementing the regulatory outcome.

74. Common Misconception: CMS Cannot Reject the RMS Assessment

Too broad.

A CMS can raise a qualifying objection under the legal framework.

The important qualification is that the formal Article 29 mechanism is tied to the statutory concept of a potential serious risk to public health.

Therefore:

CMS has regulatory independence, but disagreement is governed by a defined European procedure.

75. Common Misconception: Every CMS Concern Goes to CHMP

Incorrect.

Most questions are resolved within the ordinary MRP/DCP process.

Only qualifying unresolved disagreements proceed through the relevant escalation mechanism.

The existence of a CMS question does not itself mean that CHMP becomes involved.

76. Common Misconception: CMS Is Only Relevant Before Authorisation

Incorrect.

The CMS can remain relevant to the product's post-authorisation regulatory lifecycle.

Variations, safety procedures and other regulatory processes can involve the national authorities associated with the product.

The precise role depends on the procedure.

77. Common Misconception: CMS Is the Same as PRAC Member

Incorrect.

A CMS is a Member State regulatory role.

PRAC is an EU committee.

A national representative may participate in European structures, but the terms describe different institutional concepts.

78. Common Misconception: CMS and RMS Are Permanent Country Roles

Incorrect.

The designation is procedure-specific.

A national authority may be RMS for one product and CMS for another.

Therefore, regulatory master data should identify the role against the relevant procedure.

79. Why This Matters for Regulatory Inspections

Inspectors are interested in whether the company understands its regulatory environment.

For an MRP/DCP product, inability to identify the RMS and CMSs can indicate weak regulatory control.

More importantly, an organisation should be able to show how information from the regulatory process reaches:

The important issue is not memorising abbreviations.

It is maintaining an integrated regulatory system.

80. The CMS as Part of a Network

The EU medicines system is best understood as a network.

European Commission
       |
      EMA
       |
 +-----+------+
 |            |
CHMP         PRAC
 |

CMDh | +---+---+---+ | | | | RMS CMS CMS CMS | | | | +---+---+---+ | MAH

This is deliberately simplified.

The bodies have different legal mandates and do not form a simple reporting hierarchy.

The diagram is intended to show the network relationship, not an organisational chart.

81. The Core Concept

The CMS exists because the EU regulatory system seeks to achieve something unusual:

Multiple national authorities participating in a common regulatory assessment while retaining national regulatory responsibility.

The RMS provides the lead.

The CMSs provide participating national review.

CMDh provides European coordination.

Where necessary, EU-level procedures provide mechanisms for resolving significant disagreement.

82. Why This Concept Matters for Pharmacovigilance

When a safety issue arises, the question is not simply:

"What is the adverse event?"

It is also:

"What regulatory system governs the product?"

For an MRP/DCP product, the answer includes:

Understanding this structure allows pharmacovigilance teams to connect scientific assessment with appropriate regulatory action.

83. Key Takeaways

RMS = leads.

CMS = participates and reviews.

CMDh = coordinates.

Union procedures = resolve specified unresolved issues at EU level.

References

  1. European Medicines Agency. Concerned Member State. EMA glossary. Defines the CMS as an EEA country in which an application has been submitted for authorisation through MRP or DCP and explains its relationship with the RMS.
    https://www.ema.europa.eu/en/glossary-terms/concerned-member-state

  2. European Parliament and Council. Directive 2001/83/EC of 6 November 2001 on the Union code relating to medicinal products for human use, as amended. In particular Articles 27–29 concerning the coordination group, RMS, CMSs, MRP, DCP and disagreement procedures.
    https://eur-lex.europa.eu/eli/dir/2001/83/2022-01-01/eng

  3. European Medicines Agency. Reference Member State. EMA glossary. Defines the RMS and its role in leading MRP/DCP assessment.
    https://www.ema.europa.eu/en/glossary-terms/reference-member-state

  4. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Describes the role of CMDh in coordinating MRP/DCP questions and disagreement procedures.
    https://www.ema.europa.eu/en/committees/working-parties-other-groups/coordination-group-mutual-recognition-decentralised-procedures-human-cmdh

  5. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human. EMA glossary definition of CMDh and its regulatory scope.
    https://www.ema.europa.eu/en/glossary-terms/coordination-group-mutual-recognition-decentralised-procedures-human

  6. European Commission. Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC. Official Journal of the European Union, 2006/C 133/05.
    https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52006XC0608(02)

  7. European Medicines Agency. Referral procedures: human medicines. Explains the interaction between nationally authorised medicines, CMDh, PRAC and CHMP in applicable referral procedures.
    https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines

  8. European Medicines Agency. Authorisation of medicines. Overview of the European authorisation system and the different routes for medicinal products.
    https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines

  9. European Medicines Agency. Pre-authorisation guidance. Provides access to EU procedural guidance concerning marketing-authorisation applications and MRP/DCP.
    https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance

  10. European Medicines Agency. Abbreviations used by EMA scientific committees and CMD documents in relation to EMA regulatory activities. Confirms standard terminology including CMS and CMDh.
    https://www.ema.europa.eu/en/documents/other/abbreviations-used-ema-scientific-committees-cmd-documents-relation-emas-regulatory-activities_en.pdf

Regulatory interpretation note

This article is an educational explanation of the Concerned Member State within the EU regulatory system. It does not replace Directive 2001/83/EC, Regulation (EC) No 726/2004, Commission decisions, EMA guidance, CMDh guidance, national legislation or product-specific regulatory advice.

The precise responsibilities of a CMS depend on the type of procedure, medicinal product, regulatory stage and applicable legislation.

The terms RMS, CMS, CMDh, PRAC, CHMP and reference authority describe different regulatory concepts and should not be used interchangeably.

The diagrams and decision trees are teaching aids rather than legal flowcharts.

A CMS question, comment or request for clarification should not automatically be characterised as a formal Article 29 disagreement. The statutory threshold and procedural requirements must be assessed.

Pharmacological plausibility can contribute to scientific assessment but does not by itself establish causality. Regulatory conclusions should distinguish established evidence, supportive evidence, mechanistic plausibility and residual uncertainty.

Because EU pharmaceutical legislation and procedural guidance evolve, current primary legislation and official EMA, European Commission, CMDh and national competent-authority material should be consulted when making regulatory decisions.

Revision History

Related Articles

What Is the Reference Member State (RMS) in EU Regulatory Affairs?

A textbook-quality guide to the Reference Member State (RMS), explaining its legal role, responsibilities, relationship with CMSs and CMDh, and practical significance for regulatory affairs and pharmacovigilance.

How RMS and CMS Roles Work Together in MRP and DCP

Explains the division of assessment, review, coordination, communication and decision-making responsibilities between the RMS and CMSs without duplicating dedicated RMS and CMS articles.

What Happens When Member States Disagree During an MRP or DCP?

Explains how a CMS objection develops into a formal disagreement, the role of the coordination group, the applicant's involvement and the transition to an EU-level procedure when agreement cannot be reached.